Erik Eliasson

Om mig
Publikationer
CV
Populärvetenskap och samverkan

Om mig

Erik Eliasson är professor i farmakogenetik vid institutionen för laboratoriemedicin, avdelningen för klinisk farmakologi. Klinisk farmakologi handlar om att utveckla rationell läkemedelsbehandling och prediktiva test för vilka som riskerar biverkningar eller att svara dåligt på en behandling. Inom forskningen i farmakogenetik fokuserar man på genetiska förklaringar till biverkningar respektive dåligt behandlingssvar.

Erik Eliasson är vid sidan av sin professur även överläkare på farmakologiska laboratoriet vid Karolinska Universitetssjukhuset.

Artiklar

Article: JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE. 2025;117(4):629-636
Influence of endoxifen on mammographic density: results from the KARISMA-Tam trial
Hammarstrom M; Gabrielson M; Bergqvist J; Lundholm C; Crippa A; Backlund M; Wengstrom Y; Borgquist S; Eliasson E; Eriksson M; Tapia J; Czene K; Hall P
Article: NUCLEIC ACIDS RESEARCH. 2025;53(D1):D1498-D1509
PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes
Tremmel R; Zhou Y; Camara MD; Laarif S; Eliasson E; Lauschke VM
Article: BREAST CANCER RESEARCH AND TREATMENT. 2023;198(3):499-508
Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
Thoren L; Margolin S; Eliasson E; Bergh J; Lindh JD
Article: HUMAN GENOMICS. 2023;17(1):15
Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences
Zhou Y; Nevosadova L; Eliasson E; Lauschke VMM
Article: THERAPEUTIC DRUG MONITORING. 2023;45(1):45-54
Reproducible Quantification of Unbound Fractions of Four Beta-Lactam Antibiotics: Ultrafiltration Versus Microdialysis of Spiked Healthy Donor Plasma
Beijer G; Clarin L; oestervall J; Barclay V; Eliasson E
Article: SCIENTIFIC REPORTS. 2022;12(1):21891
Low attainment to PK/PD-targets for β-lactams in a multi-center study on the first 72 h of treatment in ICU patients
Smekal A-K; Furebring M; Eliasson E; Lipcsey M
Article: BREAST CANCER RESEARCH AND TREATMENT. 2021;190(3):451-462
Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
Thoren L; Eriksson M; Lindh JD; Czene K; Bergh J; Eliasson E; Hall P; Margolin S
Article: ANNALS OF ONCOLOGY. 2021;32(10):1286-1293
CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial
He W; Eriksson M; Eliasson E; Grassmann F; Backlund M; Gabrielson M; Hammarstrom M; Margolin S; Thoren L; Wengstrom Y; Borgquist S; Hall P; Czene K
Article: LAKARTIDNINGEN. 2021;118:20176
[Pharmacogenomics - a cornerstone of Precision Medicine. Genomic Medicine Sweden analyses genotypes associated with serious drug toxicity or therapeutic failure].
Eliasson E; Wadelius M
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2021;65(4):e02029-e02020
Poor Correlation between Meropenem and Piperacillin Plasma Concentrations and Delivered Dose of Continuous Renal Replacement Therapy
Petersson J; Giske CG; Eliasson E
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2021;87(3):1243-1252
Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles
Thoren L; Lindh JD; Ackehed G; Kringen MK; Hall P; Bergh J; Molden E; Margolin S; Eliasson E
Article: EUROPEAN RESPIRATORY JOURNAL. 2021;57(3):2003463
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
Davies Forsman L; Niward K; Kuhlin J; Zheng X; Zheng R; Ke R; Hong C; Werngren J; Paues J; Simonsson USH; Eliasson E; Hoffner S; Xu B; Alffenaar J-W; Schön T; Hu Y; Bruchfeld J
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2021;77(3):409-419
Bleeding and thromboembolism due to drug-drug interactions with non-vitamin K antagonist oral anticoagulants-a Swedish, register-based cohort study in atrial fibrillation outpatients
Holm J; Mannheimer B; Malmstrom RE; Eliasson E; Lindh JD
Article: PHARMACOGENOMICS JOURNAL. 2020;20(4):579-585
SWEDEGENE-a Swedish nation-wide DNA sample collection for pharmacogenomic studies of serious adverse drug reactions
Hallberg P; Yue Q-Y; Eliasson E; Melhus H; As J; Wadelius M
Journal article: THERAPEUTIC DRUG MONITORING. 2020;42(3):353
In Memoriam: Professor Folke Sjoqvist
Christians U; Henthorn TK; Walson PD; Oellerich M; Eliasson E
Article: JOURNAL OF CLINICAL ONCOLOGY. 2020;38(6):548-557
CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer
He W; Grassmann F; Eriksson M; Eliasson E; Margolin S; Thoren L; Hall P; Czene K
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2019;85(10):2341-2350
Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis
Svensson RJ; Niward K; Forsman LD; Bruchfeld J; Paues J; Eliasson E; Schon T; Simonsson USH
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2019;63(6):e02466-e02418
Pharmacokinetics of Caspofungin in Critically Ill Patients in Relation to Liver Dysfunction: Differential Impact of Plasma Albumin and Bilirubin Levels
Kurland S; Furebring M; Lowdin E; Eliasson E; Nielsen EI; Sjolin J
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2019;85(1):194-201
Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients
Haslemo T; Eliasson E; Jukic MM; Ingelman-Sundberg M; Molden E
Article: BMJ OPEN. 2018;8(9):e023899
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
Forsman LD; Niward K; Hu Y; Zheng R; Zheng X; Ke R; Cai W; Hong C; Li Y; Gao Y; Werngren J; Paues J; Kuhlin J; Simonsson USH; Eliasson E; Alffenaar J-W; Mansjo M; Hoffner S; Xu B; Schon T; Bruchfeld J
Article: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2018;73(10):2838-2845
Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting
Niward K; Forsman LD; Bruchfeld J; Chryssanthou E; Carlstrom O; Alomari T; Carlsson B; Pohanka A; Mansjo M; Nordvall MJ; Johansson AG; Eliasson E; Werngren J; Paues J; Simonsson USH; Schon T
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2018;62(5):e00218
Plasma Levels of Rifampin Correlate with the Tuberculosis Drug Activity Assay
Niward K; Blom LE; Forsman LD; Bruchfeld J; Eliasson E; Schon T; Chryssanthou E; Paues J
Article: CNS DRUGS. 2017;31(11):991-997
Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study
Smith RL; Haslemo T; Andreassen OA; Eliasson E; Dahl M-L; Spigset O; Molden E
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2017;121(4):239-245
Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes
Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Article: ACTA ANAESTHESIOLOGICA SCANDINAVICA. 2016;60(10):1425-1436
Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients
Petersson J; Giske CG; Eliasson E
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2016;118(6):408-414
The Role of CYP2C8 and CYP2C9 Genotypes in Losartan-Dependent Inhibition of Paclitaxel Metabolism in Human Liver Microsomes
Mukai Y; Senda A; Toda T; Eliasson E; Rane A; Inotsume N
Article: THERAPEUTIC DRUG MONITORING. 2016;38(1):127-134
Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype
Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2015;116(6):493-498
Drug-drug Interaction between Losartan and Paclitaxel in Human Liver Microsomes with Different CYP2C8 Genotypes
Mukai Y; Senda A; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Article: OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY. 2015;19(6):346-353
Differences in CYP2C9 Genotype and Enzyme Activity Between Swedes and Koreans of Relevance for Personalized Medicine: Role of Ethnicity, Genotype, Smoking, Age, and Sex
Hatta FHM; Lundblad M; Ramsjo M; Kang J-H; Roh H-K; Bertilsson L; Eliasson E; Aklillu E
Article: LAKARTIDNINGEN. 2015;112:DEDP
[Few drugs dominate among clinically important interactions. Swedish register study lists problem drugs].
Holm J; Eiermann B; Eliasson E; Mannheimer B
Article: BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2015;38(10):1673-1679
Simultaneous Determination Method of Epoxyeicosatrienoic Acids and Dihydroxyeicosatrienoic Acids by LC-MS/MS System
Mukai Y; Toda T; Takeuchi S; Senda A; Yamashita M; Eliasson E; Rane A; Inotsume N
Article: BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2015;38(12):1975-1979
Effects of Angiotensin II Receptor Blockers on Metabolism of Arachidonic Acid via CYP2C8
Senda A; Mukai Y; Toda T; Hayakawa T; Yamashita M; Eliasson E; Rane A; Inotsume N
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(11):1375-1383
A limited number of prescribed drugs account for the great majority of drug-drug interactions
Holm J; Eiermann B; Eliasson E; Mannheimer B
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2014;115(4):366-371
Plasma Levels of 25-Hydroxyvitamin D₃ and In Vivo Markers of Cytochrome P450 3A Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives
Nylen H; Bjorkhem-Bergman L; Ekstrom L; Roh H-K; Bertilsson L; Eliasson E; Lindh JD; Diczfalusy U
Article: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2014;58(8):4941-4943
Posaconazole Concentrations in Human Tissues after Allogeneic Stem Cell Transplantation
Blennow O; Eliasson E; Pettersson T; Pohanka A; Szakos A; El-Serafi I; Hassan M; Ringden O; Mattsson J
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2014;70(6):695-699
Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients
Mannheimer B; Holm J; Koukel L; Bertilsson L; Osby U; Eliasson E
Article: BIOLOGICAL & PHARMACEUTICAL BULLETIN. 2014;37(9):1550-1554
Losartan Competitively Inhibits CYP2C8-Dependent Paclitaxel Metabolism in Vitro
Mukai Y; Toda T; Hayakawa T; Eliasson E; Rane A; Inotsume N
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2013;69:S25-S32
Therapeutic drug monitoring for tomorrow
Eliasson E; Lindh JD; Malmstrom RE; Beck O; Dahl M-L
Article: DRUG METABOLISM AND DISPOSITION. 2013;41(4):704-708
Serum Levels of 25-Hydroxyvitamin D and the CYP3A Biomarker 4β-Hydroxycholesterol in a High-Dose Vitamin D Supplementation Study
Bjorkhem-Bergman L; Nylen H; Norlin A-C; Lindh JD; Ekstrom L; Eliasson E; Bergman P; Diczfalusy U
Article: PHARMACOGENOMICS. 2013;14(6):613-622
CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients
Margolin S; Lindh JD; Thoren L; Xie H; Koukel L; Dahl M-L; Eliasson E
Article: JOURNAL OF CARDIOVASCULAR PHARMACOLOGY. 2013;61(1):1-7
Influence of Simvastatin on the Thromboxane and Prostacyclin Pathways, In Vitro and In Vivo
Skogastierna C; Bjorkhem-Bergman L; Bergman P; Eliasson E; Rane A; Ekstrom L
Article: PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES. 2012;11(12):1797-1801
Vitamin D and drug-metabolising enzymes
Lindh JD; Bjorkhem-Bergman L; Eliasson E
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2012;92(2):221-227
UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems
Haslemo T; Loryan I; Ueda N; Mannheimer B; Bertilsson L; Ingelman-Sundberg M; Molden E; Eliasson E
Article: PHARMACOGENOMICS. 2012;13(7):757-762
A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele
Andersson ML; Eliasson E; Lindh JD
Article: HEART AND VESSELS. 2011;26(6):628-636
Beneficial vasoactive endothelial effects of fluvastatin: focus on prostacyclin and nitric oxide
Skogastierna C; Luksha L; Kublickiene K; Eliasson E; Rane A; Ekstrom L
Article: DRUG METABOLISM AND DISPOSITION. 2011;39(5):933-937
Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin D
Lindh JD; Andersson ML; Eliasson E; Bjorkhem-Bergman L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2010;88(3):343-346
Clinically Significant CYP2C Inhibition by Noscapine but Not by Glucosamine
Rosenborg S; Stenberg M; Otto S; Ostervall J; Masquelier M; Yue Q-Y; Bertilsson L; Eliasson E
Article: LAKARTIDNINGEN. 2010;107(22):1459
["Silent" interactions are often missed. Different combinations of pharmaceuticals can result in non-drug effect].
Mannheimer B; Eliasson E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2010;66(5):465-474
Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients
Ghotbi R; Mannheimer B; Aklillu E; Suda A; Bertilsson L; Eliasson E; Osby U
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2010;69(4):411-417
Nationwide drug-dispensing data reveal important differences in adherence to drug label recommendations on CYP2D6-dependent drug interactions
Mannheimer B; Wettermark B; Lundberg M; Pettersson H; von Bahr C; Eliasson E
Article: PHARMACOGENETICS AND GENOMICS. 2010;20(2):77-85
Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study
Nordestgaard BG; Kontula K; Benn M; Dahlof B; de Faire U; Edelman JM; Eliasson E; Fyhrquist F; Hille DA; Ibsen H; Lyle PA; Berg K; Sandbergg M; Sethi AA; Wong PH; Os I
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2009;105(5):327-332
Roles of Different CYP Enzymes in the Formation of Specific Fluvastatin Metabolites by Human Liver Microsomes
Toda T; Eliasson E; Ask B; Inotsume N; Rane A
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2008;64(12):1175-1179
Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects
Rosenborg SO; Mwinyi J; Andersson M; Baldwin RM; Pedersen RS; Sim SC; Bertilsson L; Ingelman-Sundberg M; Eliasson E
Article: THERAPEUTIC DRUG MONITORING. 2008;30(5):565-569
Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy
Mannheimer B; von Bahr C; Pettersson H; Eliasson E
Article: LAKARTIDNINGEN. 2008;105(22):1644-1645
[Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].
Eliasson E
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2008;65(5):767-774
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele;: a pharmacokinetic study in healthy volunteers
Baldwin RM; Ohlsson S; Pedersen RS; Mwinyi J; Ingelman-Sundberg M; Eliasson E; Bertilsson L
Article: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2006;15(3):179-184
Adverse drug reactions causing hospitalization can be monitored from computerized medical records and thereby indicate the quality of drug utilization
von Euler M; Eliasson E; Öhlén G; Bergman U
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2005;327(4):1052-1057
Biosynthesis of epoxyeicosatrienoic acids varies between polymorphic CYP2C enzymes
Lundblad MS; Stark K; Eliasson E; Oliw E; Rane A
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2004;279(49):50949-50955
Use of molecular simulation for mapping conformational CYP2E1 epitopes
Vidali M; Hidestrand M; Eliasson E; Mottaran E; Reale E; Rolla R; Occhino G; Albano E; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2004;60(5):337-342
CYP2C9 genetic variants and losartan oxidation in a Turkish population
Babaoglu MO; Yasar U; Sandberg M; Eliasson E; Dahl ML; Kayaalp SO; Bozkurt A
Article: CHEMICO-BIOLOGICAL INTERACTIONS. 2004;147(2):163-172
NADPH dependent activation of microsomal glutathione transferase 1
Rinaldi R; Aniya Y; Svensson R; Eliasson E; Swedmark S; Shimoji M; Morgenstern R
Article: PHARMACOGENETICS AND GENOMICS. 2003;13(12):715-720
Allelic variants of cytochromes P4502C modify the risk for acute myocardial infarction
Yasar Ü; Bennet AM; Eliasson E; Lundgren S; Wiman B; de Faire U; Rane A
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2003;59(2):103-109
Bioactivation of cyclophosphamide:: the role of polymorphic CYP2C enzymes
Griskevicius L; Yasar Ü; Sandberg M; Hidestrand M; Eliasson E; Tybring G; Hassan M; Dahl ML
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2002;299(1):25-28
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms
Yasar U; Lundgren S; Eliasson E; Bennet A; Wiman B; de Faire U; Rane A
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2002;54(4):423-429
Oxidation of celecoxib by polymorphic cytochrome P4502C9 and alcohol dehydrogenase
Sandberg M; Yasar Ü; Strömberg P; Höög JO; Eliasson E
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2001;57(10):729-735
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro
Yasar Ü; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Article: DRUG METABOLISM AND DISPOSITION. 2001;29(7):1051-1056
Role of CYP2C9 polymorphism in losartan oxidation
Yasar Ü; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Article: FEBS LETTERS. 1999;464(3):138-142
Amyloid fibril formation by pulmonary surfactant protein C
Gustafsson M; Thyberg J; Näslund J; Eliasson E; Johansson J
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;254(3):628-631
Validation of methods for CYP2C9 genotyping:: Frequencies of mutant alleles in a Swedish population
Yasar Ü; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjoqvist F
Article: CHEMICO-BIOLOGICAL INTERACTIONS. 1998;116(1-2):123-141
Interindividual variability in P450-dependent generation of neoantigens in halothane hepatitis
Eliasson E; Gardner I; Hume-Smith H; de Waziers I; Beaune P; Kenna JG
Article: JOURNAL OF HEPATOLOGY. 1998;29(5):819-825
Expression of autoantibodies to specific cytochromes P450 in a case of disulfiram hepatitis
Eliasson E; Stål P; Oksanen A; Lytton S
Article: CHEMICAL RESEARCH IN TOXICOLOGY. 1998;11(8):863-872
Immunochemical identification of hepatic protein adducts derived from estragole
Wakazono H; Gardner I; Eliasson E; Coughtrie MWH; Kenna JG; Caldwell J
Article: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS. 1996;333(2):459-465
Enzyme-specific transport of rat liver cytochrome P450 to the Golgi apparatus
Neve EPA; Eliasson E; Pronzato MA; Albano E; Marinari U; IngelmanSundberg M
Article: MOLECULAR PHARMACOLOGY. 1996;50(3):573-582
Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis
Eliasson E; Kenna JG
Article: GASTROENTEROLOGY. 1996;111(1):206-216
Cytochrome P4502E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics
Clot P; Albano E; Eliasson E; Tabone M; Arico S; Israel Y; Moncada C; IngelmanSundberg M
Article: EUROPEAN JOURNAL OF PHARMACOLOGY. 1995;293(2):123-131
STABLE EXPRESSION OF HUMAN CYTOCHROME-P450 2E1 IN V79 CHINESE-HAMSTER CELLS
SCHMALIX WA; BARRENSCHEEN M; LANDSIEDEL R; JANZOWSKI C; EISENBRAND G; GONZALEZ F; ELIASSON E; INGELMANSUNDBERG M; PERCHERMEIER M; GREIM H; DOEHMER J
Visa fler

Alla övriga publikationer

Review: ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2024;416(26):5565-5577
Development and clinical implementation of an LC-HRMS method for ivacaftor, lumacaftor, tezacaftor and elexacaftor in human plasma and breast milk.
Hansson AB; Wadström H; Eliasson E; Al Shakirchi M; de Monestrol I; Barclay V
Letter: LAKARTIDNINGEN. 2024;121:151
Nya rekommendationer för infusion av betalaktamantibiotika.
Gustafsson T; Eliasson E; Furebring M; Nielsen E; Petersson J; von Seth M; Tängden T
Review: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2022;131(6):452-464
A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing
Zhou Y; Koutsilieri S; Eliasson E; Lauschke VM
Other: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;108(6):1127-1128
Tribute to Folke Sjoqvist, a Pioneer in Clinical Pharmacology
Dahl M-L; Bergman U; Bertilsson L; Eliasson E; Gustafsson LL; Panagiotidis G; Rane A
Letter: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2017;121(4):215-216
Reply to "Multiple and Opposite Effects of Angiotensin II Receptor Blockers on the Bioavailability of Epoxyeicosatrienoic Acids'
Senda A; Mukai Y; Hayakawa T; Kato Y; Eliasson E; Rane A; Toda T; Inotsume N
Review: LAKARTIDNINGEN. 2015;112:CW3P
[Beta lactam antibiotics and the question of dose regimen for severe infection. Prolonged infusion theoretically appealing--yet no evidence of clinical benefit].
Leander G; Eliasson E; Hanberger H; Giske C
Review: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2013;45(3):161-175
Rational use of aminoglycosides-Review and recommendations by the Swedish Reference Group for Antibiotics (SRGA)
Hanberger H; Edlund C; Furebring M; Giske CG; Melhus A; Nilsson LE; Petersson J; Sjolin J; Ternhag A; Werner M; Eliasson E
Editorial comment: PHARMACOGENOMICS. 2012;13(16):1887-1891
Karolinska Institutet
Eliasson E; Sim SC; Rane A; Ingelman-Sundberg M
Letter: PHARMACOGENOMICS. 2012;13(14):1561-1562
Influence of the CYP2C9*3 allele on the pharmacological interaction between warfarin and simvastatin: author reply
Andersson ML; Eliasson E; Lindh JD
Review: JOURNAL OF INTERNAL MEDICINE. 2010;268(6):540-548
Drug-drug interactions that reduce the formation of pharmacologically active metabolites: a poorly understood problem in clinical practice
Mannheimer B; Eliasson E
Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2009;65(10):1055
Severely diminished response to vitamin K-treatment for self-inflicted warfarin intoxication in a patient genotyped as CYP2C9*3*3
Backstrom T; Barkman G; Lindh JD; Eliasson E
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2007;81(6):899-902
The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine:: Focus on antidepressants
Sjoqvist F; Eliasson E
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;80(3):301-302
Is celecoxib an inducer of cytochrome P450 3A4 in subjects carrying the CYP2C9*3 allele? Reply
Eliasson E; Lundblad MS
Editorial comment: BMJ-BRITISH MEDICAL JOURNAL. 2006;332(7551):1163-1164
Ethnicity and adverse drug reactions - Personalised drug treatment is getting closer but will not replace good clinical judgment
Eliasson E
Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2006;79(3):287-288
Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3
Lundblad MS; Ohlsson S; Johansson P; Lafolie P; Eliasson E
Published conference paper: DRUG METABOLISM AND DISPOSITION. 2004;32(5):484-489
The impact of CYP2C9 genetics and oral contraceptives on cytochrome P4502C9 phenotype
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Review: DRUG METABOLISM AND DISPOSITION. 2002;30(10):1053-1058
Reactive intermediates and the dynamics of glutathione transferases
Rinaldi R; Eliasson E; Swedmark S; Morgenstern R
Letter: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 2002;54(2):183-185
Intra-individual variability in urinary losartan oxidation ratio, an in vivo marker of CYP2C9 activity
Yasar Ü; Dahl ML; Christensen M; Eliasson E
Letter: CARCINOGENESIS. 2002;23(4):665
Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk
Yasar Ü; Eliasson E; Dahl ML
Letter: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2002;57(12):915-916
Significant reduction of sertraline plasma levels by carbamazepine and phenytoin
Pihlsgård M; Eliasson E
Published conference paper: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2002;71(1):89-98
Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype
Yasar Ü; Forslund-Bergengren C; Tybring G; Dorado P; Llerena A; Sjöqvist F; Eliasson E; Dahl ML
Letter: SURGERY. 2001;129(3):384
Mutations of the CYP2C9 gene and the response to warfarin
Yasar U; Oscarson M; Eliasson E; Sjöqvist F
Published conference paper: CHEMICO-BIOLOGICAL INTERACTIONS. 2001;133(1-3):155-158
Microsomal glutathione-S-transferase 1 activation in relation to the cytochrome P450 system
Rinaldi R; Svensson R; Eliasson E; Swedmark S; Morgenstern R
Visa fler

Om mig

Artiklar

Alla övriga publikationer

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI